JP2004531523A5 - - Google Patents

Download PDF

Info

Publication number
JP2004531523A5
JP2004531523A5 JP2002580954A JP2002580954A JP2004531523A5 JP 2004531523 A5 JP2004531523 A5 JP 2004531523A5 JP 2002580954 A JP2002580954 A JP 2002580954A JP 2002580954 A JP2002580954 A JP 2002580954A JP 2004531523 A5 JP2004531523 A5 JP 2004531523A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
amino
a3rag
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002580954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531523A (ja
Filing date
Publication date
Priority claimed from US09/832,818 external-priority patent/US20040204481A1/en
Application filed filed Critical
Publication of JP2004531523A publication Critical patent/JP2004531523A/ja
Publication of JP2004531523A5 publication Critical patent/JP2004531523A5/ja
Withdrawn legal-status Critical Current

Links

JP2002580954A 2001-04-12 2002-04-11 アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化 Withdrawn JP2004531523A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,818 US20040204481A1 (en) 2001-04-12 2001-04-12 Activation of natural killer cells by adenosine A3 receptor agonists
PCT/IL2002/000298 WO2002083152A1 (en) 2001-04-12 2002-04-11 Activation of natural killer cells by adenosine a3 receptor agonists

Publications (2)

Publication Number Publication Date
JP2004531523A JP2004531523A (ja) 2004-10-14
JP2004531523A5 true JP2004531523A5 (https=) 2005-06-30

Family

ID=25262686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002580954A Withdrawn JP2004531523A (ja) 2001-04-12 2002-04-11 アデノシンａ３レセプターアゴニストによるナチュラルキラー細胞の活性化

Country Status (7)

Country Link
US (1) US20040204481A1 (https=)
EP (1) EP1383515B1 (https=)
JP (1) JP2004531523A (https=)
AT (1) ATE284698T1 (https=)
DE (1) DE60202278T2 (https=)
IL (1) IL157841A0 (https=)
WO (1) WO2002083152A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2005117910A2 (en) 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
PL1778239T3 (pl) * 2004-07-28 2014-01-31 Can Fite Biopharma Ltd Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
MX2007003271A (es) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
CA2585581A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2010065959A1 (en) * 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CN120365435A (zh) * 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Similar Documents

Publication Publication Date Title
JP2004531523A5 (https=)
JP2003514771A5 (https=)
TWI866273B (zh) 用於治療c型肝炎病毒的核苷酸半硫酸鹽
AU2011349278B2 (en) Cyclic nucleotide analogs
JP2006524711A5 (https=)
JP2006515624A5 (https=)
CA3214726A1 (en) Nucleosides and nucleotides analogs as antiviral agents
RU2002109228A (ru) Фармацевтические композиции, содержащие агонист или антагонист аденозинового рецептора
JPH11509181A (ja) 水溶性アデノシンキナーゼ阻害剤
TW201217392A (en) Substituted nucleotide analogs
TW201808981A (zh) 用於肝臟疾病之ｄ-胺基酸化合物
WO2013142159A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
CZ183593A3 (en) Use of 1-/2/(hydroxymethyl)-1,3-oxathiazolan-5-y/5-l fluorocytosine for preparing a medicament for treating hepatitis b
JP2004517864A (ja) ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
JP2004526720A5 (https=)
AU2009200414A1 (en) Compositions and methods for combination antiviral therapy
JP2008505902A5 (https=)
CA1333361C (en) Antiviral compounds
JPH06508846A (ja) アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
JPH10139668A (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
KR900007833A (ko) 신규 2^' -할로메틸리덴 2 -에테닐리덴 및 2 -에티닐 시티딘, 우리딘 및 구아노신 유도체
NO20024324L (no) Legemidler for diagnose av vevsreproduktiv aktivitet eller behandling av proliferative sykdommer
JPH0920659A5 (https=)
US20240075033A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
JP2003520783A5 (https=)